J&J Interventional Systems stent complaint investigation procedures deficient -- FDA warning letter.
This article was originally published in The Gray Sheet
Executive SummaryJJIS' INADEQUATE INVESTIGATION OF STENT COMPLAINTS CITED BY FDA in a May 29 warning letter to Johnson & Johnson Interventional Systems' Warren, New Jersey facility. The agency says that an April 8 to 19 inspection of the facility revealed "serious violations" of good manufacturing practice regulations "concerning the processing and testing" of the firm's SDS stent delivery system used to deploy its market-leading Palmaz-Schatz coronary stent.
You may also be interested in...
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.